Cardiovascular safety and efficacy of the combined symptomatic slow-acting drug glucosamine and chondroitin sulfate in patients with gonarthrosis
Objective: to investigate the clinical efficacy and cardiovascular safety of the combined symptomatic slow-acting drug glucosamine and chondroitin sulfate in patients with osteoarthritis (OA) and hypertension.Subjects and methods. The investigation enrolled 44 patients (a female:male ratio of 40:4)...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2016-06-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/682 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839574157555138560 |
|---|---|
| author | A. P. Rebrov I. A. Romanova I. Z. Gaydukova |
| author_facet | A. P. Rebrov I. A. Romanova I. Z. Gaydukova |
| author_sort | A. P. Rebrov |
| collection | DOAJ |
| description | Objective: to investigate the clinical efficacy and cardiovascular safety of the combined symptomatic slow-acting drug glucosamine and chondroitin sulfate in patients with osteoarthritis (OA) and hypertension.Subjects and methods. The investigation enrolled 44 patients (a female:male ratio of 40:4) aged 54.5±7.4 years with knee OA (duration, 6.4±1.54 years). The patients were blindly randomized into two groups: 1) those who received antihypertensive therapy, teraflex (chondroitin sulfate 400 mg and glucosamine sulfate 500 mg) with/without acetaminophen; 2) those who had antihypertensive therapy and acetaminophen. At baseline and 3 and 6 months after treatment, the investigators assessed a change in the degree of OA by the WOMAC and Lequesne indices, the treatment efficiency evaluated by a physician and a patient using a visual analogue scale, and cardiovascular safety (during the first and last visits) through examination of the antithrombogenic properties of the vascular wall and arterial stiffness.Results. All the patients taking teraflex for 6 months were observed to have a positive effect manifesting as a substantial reduction in WOMAC and Lequesne indices, pain syndrome, and needs for analgesics compared to both the baseline level and parameters in the patients receiving acetaminophen only. Teraflex therapy showed an increase in the fibrinolytic activity of the vascular wall. A more obvious fall in augmentation index and pulse wave velocity was seen in OA and AG patients receiving antihypertensive therapy and teraflex.Conclusion. Group 1 displayed not only reductions in pain syndrome and needs for analgesics, but also no blood pressure destabilization. They also had lower endothelial dysfunction manifesting as enhanced fibrinolytic activity of the vascular wall, decreased brachial and aortic augmentation indices, and lower pulse wave velocity. |
| format | Article |
| id | doaj-art-6bc8c5005c2c48b7be0c77a9b752d3f8 |
| institution | Matheson Library |
| issn | 1996-7012 2310-158X |
| language | Russian |
| publishDate | 2016-06-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj-art-6bc8c5005c2c48b7be0c77a9b752d3f82025-08-04T14:00:33ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2016-06-01102374210.14412/1996-7012-2016-2-37-421973Cardiovascular safety and efficacy of the combined symptomatic slow-acting drug glucosamine and chondroitin sulfate in patients with gonarthrosisA. P. Rebrov0I. A. Romanova1I. Z. Gaydukova2V.I. Razumovsky Saratov State Medical University, Ministry of Health of Russia, Saratov, Russia 112, Bolshaya Sadovaya St., Saratov 410012V.I. Razumovsky Saratov State Medical University, Ministry of Health of Russia, Saratov, Russia 112, Bolshaya Sadovaya St., Saratov 410012V.I. Razumovsky Saratov State Medical University, Ministry of Health of Russia, Saratov, Russia 112, Bolshaya Sadovaya St., Saratov 410012Objective: to investigate the clinical efficacy and cardiovascular safety of the combined symptomatic slow-acting drug glucosamine and chondroitin sulfate in patients with osteoarthritis (OA) and hypertension.Subjects and methods. The investigation enrolled 44 patients (a female:male ratio of 40:4) aged 54.5±7.4 years with knee OA (duration, 6.4±1.54 years). The patients were blindly randomized into two groups: 1) those who received antihypertensive therapy, teraflex (chondroitin sulfate 400 mg and glucosamine sulfate 500 mg) with/without acetaminophen; 2) those who had antihypertensive therapy and acetaminophen. At baseline and 3 and 6 months after treatment, the investigators assessed a change in the degree of OA by the WOMAC and Lequesne indices, the treatment efficiency evaluated by a physician and a patient using a visual analogue scale, and cardiovascular safety (during the first and last visits) through examination of the antithrombogenic properties of the vascular wall and arterial stiffness.Results. All the patients taking teraflex for 6 months were observed to have a positive effect manifesting as a substantial reduction in WOMAC and Lequesne indices, pain syndrome, and needs for analgesics compared to both the baseline level and parameters in the patients receiving acetaminophen only. Teraflex therapy showed an increase in the fibrinolytic activity of the vascular wall. A more obvious fall in augmentation index and pulse wave velocity was seen in OA and AG patients receiving antihypertensive therapy and teraflex.Conclusion. Group 1 displayed not only reductions in pain syndrome and needs for analgesics, but also no blood pressure destabilization. They also had lower endothelial dysfunction manifesting as enhanced fibrinolytic activity of the vascular wall, decreased brachial and aortic augmentation indices, and lower pulse wave velocity.https://mrj.ima-press.net/mrj/article/view/682osteoarthritisgonarthrosisteraflexglucosaminechondroitin sulfate |
| spellingShingle | A. P. Rebrov I. A. Romanova I. Z. Gaydukova Cardiovascular safety and efficacy of the combined symptomatic slow-acting drug glucosamine and chondroitin sulfate in patients with gonarthrosis Современная ревматология osteoarthritis gonarthrosis teraflex glucosamine chondroitin sulfate |
| title | Cardiovascular safety and efficacy of the combined symptomatic slow-acting drug glucosamine and chondroitin sulfate in patients with gonarthrosis |
| title_full | Cardiovascular safety and efficacy of the combined symptomatic slow-acting drug glucosamine and chondroitin sulfate in patients with gonarthrosis |
| title_fullStr | Cardiovascular safety and efficacy of the combined symptomatic slow-acting drug glucosamine and chondroitin sulfate in patients with gonarthrosis |
| title_full_unstemmed | Cardiovascular safety and efficacy of the combined symptomatic slow-acting drug glucosamine and chondroitin sulfate in patients with gonarthrosis |
| title_short | Cardiovascular safety and efficacy of the combined symptomatic slow-acting drug glucosamine and chondroitin sulfate in patients with gonarthrosis |
| title_sort | cardiovascular safety and efficacy of the combined symptomatic slow acting drug glucosamine and chondroitin sulfate in patients with gonarthrosis |
| topic | osteoarthritis gonarthrosis teraflex glucosamine chondroitin sulfate |
| url | https://mrj.ima-press.net/mrj/article/view/682 |
| work_keys_str_mv | AT aprebrov cardiovascularsafetyandefficacyofthecombinedsymptomaticslowactingdrugglucosamineandchondroitinsulfateinpatientswithgonarthrosis AT iaromanova cardiovascularsafetyandefficacyofthecombinedsymptomaticslowactingdrugglucosamineandchondroitinsulfateinpatientswithgonarthrosis AT izgaydukova cardiovascularsafetyandefficacyofthecombinedsymptomaticslowactingdrugglucosamineandchondroitinsulfateinpatientswithgonarthrosis |